Nivolumab plus ipilimumab (NIVO + IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial Meeting Abstract
| Authors: | Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; Donskov, F.; Atkins, M. B.; Kollmannsberger, C. K.; Grimm, M. O.; Tomita, Y.; Rini, B. I.; Jiang, R.; Desilva, H.; Lee, C. W.; Motzer, R. J. |
| Abstract Title: | Nivolumab plus ipilimumab (NIVO + IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial |
| Meeting Title: | 2024 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2024 Jan 25-27 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-02-01 |
| Language: | English |
| ACCESSION: | WOS:001266676900475 |
| DOI: | 10.1200/JCO.2024.42.4_suppl.363 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 363 -- Source: Wos |
